摘要
Abstract
Peripheral T-cell lymphoma(PTCL)is a highly aggressive subtype of non-Hodgkin lymphoma with poor prognosis and limited efficacy of conventional chemotherapy,while significant heterogeneity in survival benefits exists among its subtypes.In recent years,advances in understanding the molecular pathological mechanisms and tumor microen-vironment of PTCL have led to emerging therapeutic options,including targeted therapies,immunotherapies,and novel com-bination strategies.In first-line treatment,the standard regimen of CD30-targeted antibody-drug conjugate brentuximab vedotin combined with chemotherapy(BV-CHP)has demonstrated improved outcomes.Further enhancements in efficacy have been achieved by integrating epigenetic agents(e.g.,HDAC inhibitors)or exploring chemotherapy-free regimens.For post-remission maintenance therapy,agents such as JAK inhibitors,HDAC inhibitors,and immunomodulatory drugs have shown potential to prolong remission duration,reduce relapse risk,and improve survival outcomes.In relapsed/re-fractory PTCL settings,novel targeted therapies(e.g.,PI3K/JAK inhibitors)and immunotherapeutic approaches(CAR-T cells,bispecific antibodies)have exhibited promising clinical activity.Moving forward,PTCL management is evolving to-ward precision medicine and multimodal strategies,with prospects for further survival improvements.This review summa-rizes recent advancements in PTCL therapeutics over the past three years,providing evidence-based references for clini-cal practice.关键词
外周T细胞淋巴瘤/维持治疗/靶向治疗/免疫疗法/治疗进展Key words
Peripheral T-cell lymphoma/Maintenance therapy/Target therapy/Immunotherapy/Therapeutic advances分类
医药卫生
